• SHARE

A team at the governmental scientific research institute Riken on Sept. 12 transplanted a retina sheet made of induced pluripotent stem (iPS) cells into a woman — the world’s first clinical research involving the transplant of human iPS cells. The surgery represents an important step that may lead to the application of iPS cells in the treatment of disease. Since iPS cells are touted as a powerful tool in the field of regenerative medicine, the world will pay attention to the results of the Riken team’s transplant.

Still, it must not be forgotten that the main purpose of this clinical research should be to confirm the safety of the transplant. Instead of trying to quickly obtain conclusions from the transplant, researchers and other parties concerned should calmly evaluate the clinical test results in a multi-faceted manner. This process will be indispensable in making regenerative medicine reliable and effective.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW